These days in the pharma world, a 483 (list of inspection observations by FDA inspectors) is pretty much a kiss of death. If you're a Director or above in Quality or Operations, you're toast.
ON the face of it, though, a consent decree is still pretty mild action. Of course, had McNeil not agreed to the consent decree, FDA would have moved forward with its lawsuit and most likely would've been found guilty of noncompliance to 21CFR Parts 210 and 211, aka the "Good Manufacturing Practices" regulations.
This will cost J&J big bucks. Consent decrees are hideously expensive, plus the requirement to bring on third party consultants to review the corrective actions and most likely, batch records prior to release, also ain't cheap.
FDA is empowered to conduct seizures and, if they have a mind to, to proceed forward on a criminal basis against individuals - it's pretty rare, but it has happened.